The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis

Not Applicable

Completed

• Conditions: Severe Sepsis
• Interventions: Drug: natural saline; Drug: Esmolol

• Registration Number: NCT02794025
• Lead Sponsor: Fujian Provincial Hospital

Brief Summary

The purpose of this study was to investigate the effect of esmolol on hemodynamic parameters,tissue perfusion and the clinical prognosis of patients with severe sepsis

Detailed Description

enrollment:151 patients

Inclusion criteria: (1) age \> 18 years; (2) severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and Septic Shock, who (3) mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg; and (4) satisfactory sedation and analgesic treatment, with HR \> 100 bpm.

Study Timeline

• Study Start: 2010-01
• Primary Completion: 2013-01
• Study Completion: 2013-01
• Status Verified: 2016-06
• Study First Submitted: 2016-06-04
• Study First Submitted QC: 2016-06-07
• Last Update Submitted: 2016-06-07
• Study First Posted: 2016-06-08
• Last Update Posted: 2016-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 151

Inclusion Criteria

• age > 18 years;
• severe sepsis (acute organ dysfunction secondary to infection )diagnosis according to Campaign to Save Septic Patients: 2008 Treatment Guidelines for Severe Sepsis and Septic Shock,
• mechanical ventilation via endotracheal intubation with a tidal volume of 6 mL/kg;
• satisfactory sedation and analgesic treatment, with HR > 100 bpm.

Exclusion Criteria

• pre-existing cardiac dysfunction, valvular heart disease, high-degree atrioventricular block;
• acute or chronic pulmonary heart disease;
• a history of serious asthma;
• chronic renal insufficiency;
• cancer, autoimmune diseases, or contraindications for placement of deep venous catheter;
• insulin-dependent diabetes.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control group	natural saline	Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
esmolol group	Esmolol	patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.

Primary Outcome Measures

Name	Time	Method
The survival time of patients more than 28 days is defined as survival. The survival time of patients less than 28 days is defined as death.	28 days